Basis: Current FMP quote-based enterprise value / matching reported total assets. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Assets ratio is 1.02x as of 2026-10-06T14:27:03.265Z.
Calculation as of: 2026-10-06T14:27:03.265Z.
Quote observation: 2026-10-06T14:24:58.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/ASSETS RATIO
1.02x
SECTOR MEDIAN · HEALTHCARE
1.51x
median of 539 covered companies
CURRENT VS SECTOR MEDIAN
-32.45%
vs the sector median at left
Kailera Therapeutics, Inc.
Market Cap
$1.36B
EV/Assets Ratio
1.02x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
EV/Assets Ratio
8.18x
TTM Avg
7.21x
3Y Avg
3.86x
5Y Avg
4.55x
Market Cap
$1.32B
EV/Assets Ratio
2.31x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.31B
EV/Assets Ratio
9.71x
TTM Avg
6.84x
3Y Avg
3.74x
5Y Avg
3.43x
Market Cap
$1.45B
EV/Assets Ratio
2.47x
TTM Avg
3.32x
3Y Avg
2.61x
5Y Avg
2.61x
Market Cap
$1.46B
EV/Assets Ratio
1.60x
TTM Avg
1.66x
3Y Avg
1.27x
5Y Avg
1.35x
| NAME | MARKET CAP | EV/ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.36B | 1.02x | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | 8.18x | 7.21x | 3.86x | 4.55x |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.32B | 2.31x | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.31B | 9.71x | 6.84x | 3.74x | 3.43x |
| AnaptysBio, Inc. (ANAB)vs › | $1.41B | 4.89x | 4.11x | 1.99x | 1.45x |
| Braveheart Bio, Inc. (BRVE)vs › | $1.43B | N/A | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | 2.47x | 3.32x | 2.61x | 2.61x |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.46B | 1.60x | 1.66x | 1.27x | 1.35x |
| GH Research PLC (GHRS)vs › | $1.48B | 3.05x | 3.15x | 2.26x | 2.02x |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.49B | 12.88x | 8.36x | 6.03x | 4.88x |
EV/Assets compares enterprise value to total assets. It is useful for asset-heavy businesses and for comparing how much the market pays for each dollar of assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
